FEDERALhearing transcript

Senate Hearing on Alzheimer's Testing, Treatment, and Costs

Original title: THE ALZHEIMER'S CRISIS: EXAMINING TESTING AND TREATMENT PIPELINES AND FISCAL IMPLICATIONS

January 1, 2022

Alzheimer's disease healthcare medical research fiscal policy Senate Finance Committee

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

The Frame

What this does

This hearing serves as a formal record of legislative inquiry into the medical research landscape and federal fiscal implications of Alzheimer's disease, which currently has no cure or treatment to stop its progression.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Alzheimer's patients and families

They are the primary population impacted by the lack of effective treatments and the fiscal costs associated with long-term care.

Medical research institutions

These organizations are involved in the development of testing and treatment pipelines discussed by the committee.

What changed

Last recorded activity January 1, 2022.

What's next

Next step not available in the current record.

Summary

The Senate Finance Subcommittee on Health Care held a hearing on December 16, 2020, to discuss the medical and fiscal challenges posed by Alzheimer's disease. Experts and lawmakers examined current research s for testing and treatment, as well as the long-term economic impact of the disease.

Key Facts

The hearing was held on December 16, 2020, via WebEx.
The subcommittee focused on the 'testing and treatment pipelines' for Alzheimer's disease.
The hearing addressed the fiscal implications of Alzheimer's for the federal government.
Chairman Toomey stated that Alzheimer's disease is currently 100-percent fatal.
There is currently no therapeutic intervention that can reverse, stop, or slow the progression of Alzheimer's disease.
The hearing included testimony from four expert witnesses representing medical research and advocacy organizations.
The record includes responses to follow-up questions from subcommittee members provided by the witnesses.

Frequently Asked Questions

What was the purpose of this hearing?

The hearing was held to examine the current state of Alzheimer's research, specifically focusing on how new tests and treatments are developed and the resulting fiscal impact on the healthcare system.

Who testified at the hearing?

Experts from the Pennsylvania State College of Medicine, Washington University School of Medicine, the Global Alzheimer's Platform Foundation, and the Alzheimer's Association provided testimony.

Why It Matters

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

Focus on Fiscal Implications

The hearing explicitly links medical research progress to federal fiscal sustainability, indicating a shift toward viewing Alzheimer's as a budgetary challenge as much as a medical one.

Senate Finance Subcommittee on Health Care

Connected Entities

personRandall J. Bateman“Witness, Washington University School of Medicine”Map →

personDebbie Stabenow“Ranking member of the subcommittee”Map →

personNikolay Dokholyan“Witness, Penn State College of Medicine”Map →

personRichard C. Mohs“Witness, Global Alzheimer's Platform Foundation”Map →

personPatrick J. Toomey“Chairman of the Subcommittee on Health Care”Map →

organizationSenate Finance Subcommittee on Health Care“Committee conducting the hearing”Map →

personMaria Carrillo“Witness, Alzheimer's Association”Map →

Sources

Open source document

www.govinfo.gov

Analysis Score

0–100

Significance60
How much this matters to a regular citizen
Controversy10
Intensity of disagreement among stakeholders
Entertainment5
Compellingness for a non-policy-wonk reader
Buzz10
Current news / social attention level

Publisher tools